Soyupek Feray, Soyupek Sedat, Perk Hakki, Ozorak Alper
Department of Physical Medicine and Rehabilitation, Suleyman Demirel University School of Medicine, Isparta, Turkey.
Urol Oncol. 2008 Mar-Apr;26(2):141-6. doi: 10.1016/j.urolonc.2006.12.014. Epub 2007 Oct 29.
Prostate cancer is the most frequently diagnosed malignancy. Luteinizing hormone-releasing hormone (LH-RH) agonists are used in most patients with locally advanced and metastatic prostate cancer, and decrease testosterone production. We aimed to find out the effects of androgen deprivation therapy with LH-RH agonist on the hand function, quality of life, and mood of the patients with prostate cancer.
A total of 20 patients with locally advanced prostate cancer and 20 age-matched healthy men were included in the study as LH-RH and control groups, respectively.
Age, body mass index, occupation and dominant hand, physical activity level, Beck depression inventory scores, 15D quality of life questionnaire scores, and Duruoz hand index scores were recorded. Handgrip strength was tested in the dominant hand using the Jamar hand dynamometer (Sammons Preston, Inc., Bollingbrook, IL). The Grooved Pegboard Test was used to test manual dexterity. Serum concentrations of total and free testosterone, estradiol levels were measured.
There were no differences between the groups in body mass index, physical activity level, and age (P > 0.05). Serum total and free testosterone, estradiol level, and the mean grip strength score were statistically lower in the LH-RH group. Manual dexterity was diminished in the LH-RH group (P < 0.001). The Duruoz hand index, and Beck depression inventory and 15D quality of life questionnaire scores were statistically lower in the LH-RH group (P < 0.005). We found a correlation between handgrip strength, dexterity, Beck depression inventory scores, 15D quality of life questionnaire scores, and total and free testosterone.
Men with low testosterone levels caused by androgen deprivation therapy have worse grip strength, dexterity, 15D quality of life questionnaire scores, and depressive symptoms than age-matched men who have not received androgen deprivation therapy.
前列腺癌是最常被诊断出的恶性肿瘤。促黄体生成素释放激素（LH-RH）激动剂被用于大多数局部晚期和转移性前列腺癌患者，可降低睾酮生成。我们旨在探究使用LH-RH激动剂进行雄激素剥夺治疗对前列腺癌患者手部功能、生活质量和情绪的影响。
本研究共纳入20例局部晚期前列腺癌患者和20例年龄匹配的健康男性，分别作为LH-RH组和对照组。
记录年龄、体重指数、职业和优势手、身体活动水平、贝克抑郁量表评分、15D生活质量问卷评分以及杜罗兹手部指数评分。使用Jamar握力计（Sammons Preston公司，伊利诺伊州博林布鲁克）测试优势手的握力。使用带槽钉板试验测试手部灵活性。测量血清总睾酮、游离睾酮浓度以及雌二醇水平。
两组在体重指数、身体活动水平和年龄方面无差异（P>0.05）。LH-RH组的血清总睾酮、游离睾酮、雌二醇水平以及平均握力评分在统计学上较低。LH-RH组的手部灵活性降低（P<0.001）。LH-RH组的杜罗兹手部指数、贝克抑郁量表以及15D生活质量问卷评分在统计学上较低（P<0.005）。我们发现握力、灵活性、贝克抑郁量表评分、15D生活质量问卷评分与总睾酮和游离睾酮之间存在相关性。
与未接受雄激素剥夺治疗的年龄匹配男性相比，因雄激素剥夺治疗导致睾酮水平较低的男性握力、灵活性、15D生活质量问卷评分以及抑郁症状更差。
